Evaluation of a polysaccharide conjugate vaccine to reduce colonization by Campylobacter jejuni in broiler chickens

被引：26
作者：
Hodgins D.C. [1 ]
Barjesteh N. [1 ]
St. Paul M. [1 ,3 ]
Ma Z. [2 ]
Monteiro M.A. [2 ]
Sharif S. [1 ]
机构：
[1] Department of Pathobiology, University of Guelph, Guelph, N1G 2W1, ON
[2] Department of Chemistry, University of Guelph, Guelph
[3] Department of Immunology, University of Toronto, Toronto, ON
来源：
BMC Research Notes | / 8卷 / 1期
基金：
加拿大自然科学与工程研究理事会;
关键词：
Broiler chickens; Campylobacter jejuni; Capsular polysaccharide; Cecum; Conjugate vaccine; Vaccination;
D O I：
10.1186/s13104-015-1203-z
中图分类号：
学科分类号：
摘要：
Background: Campylobacter jejuni is a leading bacterial cause of food-borne illness in humans. Symptoms range from mild gastroenteritis to dysentery. Contaminated chicken meat is the most common cause of infection. Broiler chickens become colonized with high numbers of C. jejuni in the intestinal tract, but do not become clinically ill. Vaccination of broiler chicks to control colonization by C. jejuni is challenging because immune function is limited in the first 2 weeks post-hatch and immune suppressive maternal antibodies are common. In addition, there is little time for induction of immunity, since broilers reach slaughter weight by 5-6 weeks of age. In the current study the immunogenicity of a C. jejuni capsular polysaccharide - diphtheria toxoid conjugated vaccine (CPSconj), administered subcutaneously with various adjuvants was assessed and the efficacy of vaccination for reducing cecal colonization after experimental challenge was evaluated by determining colony-forming units (CFU) of C. jejuni in cecal contents. Results: The CPSconj vaccine was immunogenic when administered as three doses at 3, 4 and 5 weeks of age to specific pathogen free chicks lacking maternal antibodies (seroconversion rates up to 75%). Commercial broiler chicks (having maternal antibodies) receiving two doses of CPSconj vaccine at 7 and 21 days of age did not seroconvert before oral challenge at 29 days, but 33% seroconverted post challenge; none of the placebo-injected, challenged birds seroconverted. Vaccinated birds had significantly lower numbers of C. jejuni in cecal contents than control birds at necropsy (38 days of age). CFU of C. jejuni did not differ significantly among groups of birds receiving CPSconj vaccine with different adjuvants. In two trials, the mean reduction in CFU associated with vaccination was 0.64 log10 units. Conclusions: The CPSconj vaccine was immunogenic in chicks lacking maternal antibodies, vaccinated beginning at 3 weeks of age. In commercial broiler birds (possessing maternal antibodies) vaccinated at 7 and 21 days of age, 33% of birds seroconverted by 9 days after challenge, and there was a modest, but significant, reduction in cecal counts of C. jejuni. Further studies are needed to optimize adjuvant, route of delivery and scheduling of administration of this vaccine. © 2015 Hodgins et al.
引用
收藏
相关论文
共 37 条
  • [11] Widders P.R., Perry R., Muir W.I., Husband A.J., Long K.A., Immunisation of chickens to reduce intestinal colonization with Campylobacter jejuni, Br Poult Sci, 37, pp. 765-778, (1996)
  • [12] Wyszynska A., Raczko A., Lis M., Jagusztyn-Krynicka E.K., Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter, Vaccine, 22, pp. 1379-1389, (2004)
  • [13] Layton S.L., Morgan M.J., Cole K., Kwon Y.M., Donoghue D.J., Hargis B.M., Et al., Evaluation of Salmonella-vectored Campylobacter peptide epitopes for reduction of Campylobacter jejuni in broiler chickens, Clin Vaccine Immunol, 18, pp. 449-454, (2011)
  • [14] Buckley A.M., Wang J., Hudson D.L., Grant A.J., Jones M.A., Maskell D.J., Et al., Evaluation of live-attenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry, Vaccine, 28, pp. 1094-1105, (2010)
  • [15] Huang J.L., Yin Y.X., Pan Z.M., Zhang G., Zhu A.P., Liu X.F., Et al., Intranasal immunization with chitosan/pCAGGS-flaA nanoparticles inhibits Campylobacter jejuni in a White Leghorn model, J Biomed Biotechnol, (2010)
  • [16] Khoury C.A., Meinersmann R.F., A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine, Avian Dis, 39, pp. 812-820, (1995)
  • [17] Monteiro M.A., Baqar S., Hall E.R., Chen Y.-H., Porter C.K., Bentzel D.E., Et al., Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni, Infect Immun, 77, pp. 1128-1136, (2009)
  • [18] Guerry P., Poly F., Riddle M., Maue A.C., Chen Y.H., Monteiro M.A., Campylobacter polysaccharide capsules: Virulence and vaccines, Front Cell Infect Microbiol, 2, (2012)
  • [19] Bertolo L., Ewing C.P., Maue A., Poly F., Guerry P., Monteiro M.A., The design of a capsule polysaccharide conjugate vaccine against Campylobacter jejuni serotype HS15, Carbohydr Res, 366, pp. 45-49, (2013)
  • [20] Maue A.C., Mohawk K.L., Giles D.K., Poly F., Ewing C.P., Jiao Y., Et al., The polysaccharide capsule of Campylobacter jejuni modulates the host immune response, Infect Immun, 81, pp. 665-672, (2013)
1234